Press release
Focal Segmental Glomerulosclerosis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | B. Braun Melsungen, Beckman Coulter (Danaher), Baxter International, ChemoCentryx, Complexa, Dimerix, Medt
"Focal Segmental Glomerulosclerosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.
The Focal Segmental Glomerulosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report: https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Focal Segmental Glomerulosclerosis treatment therapies with a considerable amount of success over the years.
• Focal Segmental Glomerulosclerosis companies working in the treatment market are Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp, Dimerix Bioscience, Travere Therapeutics, Inc., and others, are developing therapies for the Focal Segmental Glomerulosclerosis treatment
• Emerging Focal Segmental Glomerulosclerosis therapies in the different phases of clinical trials are- Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, and others are expected to have a significant impact on the Focal Segmental Glomerulosclerosis market in the coming years.
• In August 2022, The company finished its scheduled Type A meeting with the FDA regarding a potential submission seeking accelerated approval for sparsentan to treat FSGS. The FDA suggested that the study's design in the DUPLEX Study retained the possibility for complete approval, contingent on the study's completion, and advised the company to pursue standard approval based on the two-year eGFR slope.
• In February 2022, Goldfinch Bio revealed encouraging initial findings from a phase 2 clinical study assessing gfb-887 as a personalized medicine for individuals diagnosed with focal segmental glomerulosclerosis (FSGS).
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a kidney disorder that affects the glomeruli, which are tiny blood vessels in the kidneys that filter waste and excess fluids from the blood to form urine. In FSGS, scar tissue develops in some of the glomeruli, leading to problems with kidney function.
Get a Free Sample PDF Report to know more about Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Focal Segmental Glomerulosclerosis Drugs Under Different Phases of Clinical Development Include:
• Research programme Oligonucleotides: Ceptur Therapeutics
• EG-102: Evergreen Therapeutics
• D4-101-02: Delta4
• OCX-063: Certa Therapeutics
• BI764198: Boehringer Ingelheim
• R3R 01: River 3 Renal Corp
• DMX-200: Dimerix Bioscience
• Sparsentan: Travere Therapeutics, Inc.
Focal Segmental Glomerulosclerosis Route of Administration
Focal Segmental Glomerulosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
Focal Segmental Glomerulosclerosis Molecule Type
Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment
• Focal Segmental Glomerulosclerosis Assessment by Product Type
• Focal Segmental Glomerulosclerosis By Stage and Product Type
• Focal Segmental Glomerulosclerosis Assessment by Route of Administration
• Focal Segmental Glomerulosclerosis By Stage and Route of Administration
• Focal Segmental Glomerulosclerosis Assessment by Molecule Type
• Focal Segmental Glomerulosclerosis by Stage and Molecule Type
DelveInsight's Focal Segmental Glomerulosclerosis Report covers around 18+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Focal Segmental Glomerulosclerosis product details are provided in the report. Download the Focal Segmental Glomerulosclerosis pipeline report to learn more about the emerging Focal Segmental Glomerulosclerosis therapies
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Focal Segmental Glomerulosclerosis Therapeutics Market include:
Key companies developing therapies for Focal Segmental Glomerulosclerosis are - B. Braun Melsungen AG, Beckman Coulter Inc. (Danaher), Baxter International Inc., ChemoCentryx Inc., Complexa Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Retrophin Inc., Variant Pharmaceuticals Inc., and others.
Focal Segmental Glomerulosclerosis Pipeline Analysis:
The Focal Segmental Glomerulosclerosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Focal Segmental Glomerulosclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Focal Segmental Glomerulosclerosis Treatment.
• Focal Segmental Glomerulosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Focal Segmental Glomerulosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Focal Segmental Glomerulosclerosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Focal Segmental Glomerulosclerosis drugs and therapies
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Pipeline Market Drivers
• Surge of interest in developing new therapies for FSGS, renaissance in clinical research in nephrology are some of the important factors that are fueling the Focal Segmental Glomerulosclerosis Market.
Focal Segmental Glomerulosclerosis Pipeline Market Barriers
• However, the etiology and pathogenesis of Focal Segmental Glomerulosclerosis are very complex, high cost associated with the disease and other factors are creating obstacles in the Focal Segmental Glomerulosclerosis Market growth.
Scope of Focal Segmental Glomerulosclerosis Pipeline Drug Insight
• Coverage: Global
• Key Focal Segmental Glomerulosclerosis Companies: Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp, Dimerix Bioscience, Travere Therapeutics, Inc., and others
• Key Focal Segmental Glomerulosclerosis Therapies: Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, and others
• Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
• Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
Request for Sample PDF Report for Focal Segmental Glomerulosclerosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Focal Segmental Glomerulosclerosis Report Introduction
2. Focal Segmental Glomerulosclerosis Executive Summary
3. Focal Segmental Glomerulosclerosis Overview
4. Focal Segmental Glomerulosclerosis- Analytical Perspective In-depth Commercial Assessment
5. Focal Segmental Glomerulosclerosis Pipeline Therapeutics
6. Focal Segmental Glomerulosclerosis Late Stage Products (Phase II/III)
7. Focal Segmental Glomerulosclerosis Mid Stage Products (Phase II)
8. Focal Segmental Glomerulosclerosis Early Stage Products (Phase I)
9. Focal Segmental Glomerulosclerosis Preclinical Stage Products
10. Focal Segmental Glomerulosclerosis Therapeutics Assessment
11. Focal Segmental Glomerulosclerosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Focal Segmental Glomerulosclerosis Key Companies
14. Focal Segmental Glomerulosclerosis Key Products
15. Focal Segmental Glomerulosclerosis Unmet Needs
16 . Focal Segmental Glomerulosclerosis Market Drivers and Barriers
17. Focal Segmental Glomerulosclerosis Future Perspectives and Conclusion
18. Focal Segmental Glomerulosclerosis Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Focal Segmental Glomerulosclerosis Epidemiology https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Focal Segmental Glomerulosclerosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Orthopedic Trauma Devices Market https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market
Global Orthopedic Trauma Devices Market was valued at USD 7.01 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 10.15 billion by 2030. The demand for orthopedic trauma devices is witnessing growth due to the rising number of accident and trauma cases, growing prevalence of degenerative bone disorders, the rising number of sports-related injuries, rising demand for technologically advanced products, and increasing geriatric population are expected to drive product demand in the global orthopedic trauma devices market.
Acute Ischemic Stroke Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of acute ischemic stroke in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Advanced Wound Care Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
As per DelveInsight, the global Advanced Wound Care Market was valued at USD 10.44 billion in 2023, growing at a CAGR of 10.82% during the forecast period from 2024 to 2030, to reach USD 19.29 billion by 2030. The demand for advanced wound care is predominantly associated with the rising incidence of chronic wounds associated with various chronic disorders such as diabetes, and cancer, and also with the rising incidence of active wounds comprising burns, and surgical wounds, among others
Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | B. Braun Melsungen, Beckman Coulter (Danaher), Baxter International, ChemoCentryx, Complexa, Dimerix, Medt here
News-ID: 3560738 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Focal
Focal Epilepsy Market New Product Development & Latest Trends
Introduction
Focal epilepsy, the most common form of epilepsy worldwide, originates in specific regions of the brain and often presents with partial seizures. Affecting millions of people globally, focal epilepsy remains a pressing neurological challenge with significant clinical and economic impact. Increasing diagnosis rates, technological advances in imaging and neurostimulation, and new pharmacological approaches are fueling rapid changes in the treatment landscape.
As healthcare systems place greater emphasis on effective long-term management…
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
